In a follow‐up study of patients with relapsed/refractory AML, where 65% of subjects received >2 lines of therapy and 23% received treatment with a TKI, the overall response rate was 55% (60% for FLT3‐mutated patients and 29% for FLT3 wild‐type patients) in the setting of a median overall survival of 29 weeks 43. Here, FLT3 is linked to acute myeloid leukemia.